Presentation and Status in Health Basket
IMPORTANT: Intron A Interferon alfa-2b, recombinant for Injection dosing
regimens are different for each of the following indications described in this
section of the product information sheet.
Chronic hepatitis B: The recommended dose is in the range 5 to 10 million IU administered subcutaneously three times a week (every other day) for a period of 4 to 6 months.
Chronic hepatitis C: Intron A is administered subcutaneously at a dose of 3 million IU three times a week (every other day) to adult patients, whether administered as monotherapy or in combination with ribavirin.
Hairy cell leukaemia: The recommended dose is 2 million IU/m² administered subcutaneously three times a week (every other day) for both splenectomised and non-splenectomised patients.
Chronic myelogenous leukaemia: The recommended dose of Intron A is 4 to 5 million IU/m² administered daily subcutaneously.
Non-Hodgkin’s lymphoma (follicular lymphoma): Adjunctively with chemotherapy, interferon alfa-2b may be administered subcutaneously, at a dose of 5 million IU three times a week (every other day) for a duration of 18
Malignant melanoma: As induction therapy, interferon alfa-2b is administered intravenously at a dose of 20 million IU/m² daily for five days a week for a four-week period; the calculated interferon alfa-2b dose is added to sodium chloride 9 mg/ml (0.9 %) solution for injection and administered as a 20-minute infusion.
AIDS-related Kaposi’s sarcoma: The optimal dosage is not yet known.
Metastatic renal cell carcinoma: As monotherapy: Optimal dose and schedule have not been determined. In combination with other therapeutic agents, such as interleukin-2: Optimal dose has not been determined.
See prescribing information for full details.
Chronic hepatitis B, chronic hepatitis C, hairy cell leukemia, chronic myelogenous leukemia, AIDS related Kaposi’s sarcoma, malignant melanoma, metastatic/recurrent renal cell carcinoma, non-Hodgkin’s lymphoma, high tumor burden follicular lymphoma as adjunct to apropriate combination induction chemotherapy such as a CHOP like regimen.
Signs of portal hypertension, chronic hepatitis, hypersensitivity, patients with rapidly progressive visceral disease. No aspirin or (NSAID) drugs should be given to patients treated with interferon.
Depression, suicidal thoughts, psychiatric treatment which may constitute a risk factor for treatment, lung disease, diabetes, coagulation disorders, cardiovascular disease and psoriasis. Adequate hydration should be maintained. Administration of Intron-A injection in combination with other chemotherapeutic agents.
Changes in visual acuity or visual fields.
Centrally acting drugs. Phenytoin, theophylline, coumarin anticoagulants. Other neurotoxic, hematoxic or cardiotoxic drugs. Drugs metabolized by the liver, other immunomodulators.